^
Association details:
Biomarker:B2M elevation
Cancer:Multiple Myeloma
Regimen: (bortezomib + cyclophosphamide + dexamethasone injection)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

CLINICAL FACTORS DETERMINING THE SURVIVAL OF MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE: A SINGLE-CENTER EXPERIENCE

Published date:
05/11/2023
Excerpt:
Twenty-seven percent of MM patients were found to have EMD....Most commonly used induction regimen was bortezomib-cyclophosphamide-dexamethasone (VCD) regimen (36%)….In the univariate analysis; advanced ISS staging (OS HR: 2.42, p = 0.024), high levels of serum Beta-2-Microglobulin (OS HR: 2.46, p = 0.020), and light chain disease (OS median survival 24 months / 78 months, p = 0.049) were associated with a worse OS....Our study showed that various clinicals factors including ISS staging, levels of serum Beta-2-Microglobulin and creatinine and EMD subtypes were associated with inferior outcome.